Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death
FDA approves belzutifan with pembrolizumab for kidney cancer; phase III trial reduced recurrence/death 28% (HR 0.72) with 80.7% disease-free survival at 2 years. For biotech IT leaders, this validates precision medicine combination therapies influencing clinical software investment decisions.
— Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death
June 12, 2026
• 2 min read
The FDA on Friday approved belzutifan (Welireg) plus pembrolizumab (Keytruda, Keytruda Qlex) as adjuvant therapy for renal cell carcinoma (RCC) with a clear cell component.
Based on results from LITESPARK-022, the combination is indicated for adults at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
The FDA approved belzutifan with pembrolizumab as an adjuvant treatment for adults with clear cell renal cell carcinoma and a…
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG®…
Merck wins FDA approval for Welireg+Keytruda in adjuvant clear cell kidney cancer, after study showed a 28% risk reduction vs.…
Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | The…
Combination significantly improved disease-free survival in phase III trial
Antibody-drug conjugate plus pembrolizumab superior to pembrolizumab alone in PD-L1 expressors
FDA approves belzutifan with pembrolizumab as adjuvant for renal cell carcinoma
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
